

Medtronic

8-year outcomes

Physician insights

Registry quick facts

Endurant™
stent graft system

The new standard for EVAR durability

ENGAGE OUS Registry 8-year results: Endurant is THE ONLY endograft to demonstrate that 1-year sac regression is an early indicator for high 8-year sac regression and lower ACM, secondary procedures, and endoleaks.¹



¹ Hence J.M. Verhagen, Dittmar Böckler, Ian M. Loftus, Michel M.P.J. Reijnen, Frank R. Arko III, Joep Teijink, Brett Peterson, Marc L. Schermerhorn. How Sac Regression at 1 Y affects All-Cause Mortality at Extended Timepoints: Key Insights from the ENGAGE Registry Charing Cross International Symposium, 26-28 April 2022, London UK. First to Podium.



8-year outcomes

Physician insights

Registry quick facts

Durable clinical outcomes | AAA sac status

More data ▶

The goal of EVAR is to prevent ARM (Aneurysm Related Mortality)

Endurant delivers low ARM and durability via sac regression through 8 years.

FF ARM	99.0 + 0.8%
FF rupture	99.2 + 0.7%
FF conversion	98.5 + 1.2%

¹ Hence J.M. Verhagen, Dittmar Böckler, Ian M. Loftus, Michel M.P.J. Reijnen, Frank R. Arko III, Joep Teijink, Brett Peterson, Marc L. Schermerhorn. How Sac Regression at 1 Y affects All-Cause Mortality at Extended Timepoints: Key Insights from the ENGAGE Registry Charing Cross International Symposium, 26-28 April 2022, London UK. First to Podium.



8-year outcomes

Physician insights

Registry quick facts

Durable clinical outcomes | AAA sac status

◀ More data

Endurant™ stent graft system demonstrates durability

Endurant is the **ONLY** endograft to demonstrate that **1-year sac regression is an early indicator for high 8-year sac regression and lower ACM, secondary procedures, and endoleaks.**¹

	Sac decrease	Sac stable		
FF ACM	61.9 ± 3.1%	56.4 ± 3.1%	p=.035	statistically significant
FF Secondary procedures	80.7 ± 3.1%	69.6 ± 3.8%	p=.002	statistically significant
FF any endoleak	68.4 ± 2.3%	52.9 ± 2.4%	p<.0001	statistically significant

¹ Hence J.M. Verhagen, Dittmar Böckler, Ian M. Loftus, Michel M.P.J. Reijnen, Frank R. Arko III, Joep Teijink, Brett Peterson, Marc L. Schermerhorn. How Sac Regression at 1 Y affects All-Cause Mortality at Extended Timepoints: Key Insights from the ENGAGE Registry Charing Cross International Symposium, 26-28 April 2022, London UK. First to Podium.



8-year outcomes


Physician insights

Registry quick facts

Durable clinical outcomes | [AAA sac status](#)

Endurant™ stent graft system is the ONLY endograft to demonstrate that sac regression at 1 year is an early indicator for high sac regression through 8 years and related clinical benefits.¹

1-year sac status



8-year sac status



Show

¹ Hence J.M. Verhagen, Dittmar Böckler, Ian M. Loftus, Michel M.P.J. Reijnen, Frank R. Arko III, Joep Tejjink, Brett Peterson, Marc L. Schermerhorn. How Sac Regression at 1 Y affects All-Cause Mortality at Extended Timepoints: Key Insights from the ENGAGE Registry Charing Cross International Symposium, 26-28 April 2022, London UK. First to Podium.



8-year outcomes


Physician insights

Registry quick facts


Durable clinical outcomes | AAA sac status

Endurant™ stent graft system is the ONLY endograft to demonstrate that sac regression at 1 year is an early indicator for high sac regression through 8 years and related clinical benefits.¹

1-year sac status



8-year sac status



84% of Endurant patients with available images at 8-yr and who had sac regression at 1-year, demonstrated persistent sac regression at 8 years.¹

¹ Hence J.M. Verhagen, Dittmar Böckler, Ian M. Loftus, Michel M.P.J. Reijnen, Frank R. Arko III, Joep Tejjink, Brett Peterson, Marc L. Schermerhorn. How Sac Regression at 1 Y affects All-Cause Mortality at Extended Timepoints: Key Insights from the ENGAGE Registry Charing Cross International Symposium, 26-28 April 2022, London UK. First to Podium.



8-year outcomes

Physician insights

Registry quick facts

Physician insights



// This ground-breaking data definitively shows that with Endurant, sac regression at 1 year is directly tied to significantly lower endoleaks, secondary procedures & all-cause mortality indicating these patients at 1 year can have a less rigorous follow-up for first 5 years. Sac regression with Endurant is the new paradigm for success. We now have a new standard for EVAR durability."

Professor Hence Verhagen, MD, PhD



8-year outcomes

Physician insights

Registry quick facts

Study goal

Gather long-term evidence on performance of Endurant™ stent graft system in real-world population

Real-world patients


1,263
patients

390
patients
consented
to ten years^{1,2}


79
centers


30 **6**
countries continents


follow-up is
ongoing through
10 years

100%
data management review

Independent clinical event committee adjudicating all deaths
Continuous data monitoring through 10 years

94%
clinical follow up at 8-year

83%
imaging follow up at 8-year

¹ Teijink J, Power A, van Sterkenburg S, et al. 8-Year Data from the ENGAGE Registry Extension: Insights about the Long-term Performance of a Contemporary EVAR Device. Presentation presented online at: ESVS 35th Annual Meeting. September 20, 2021.

² Teijink JAW, Power AH, Böckler D, et al. Editor's Choice - Five Year Outcomes of the Endurant Stent Graft for Endovascular Abdominal Aortic Aneurysm Repair in the ENGAGE Registry. Eur J Vasc Endovasc Surg. August 2019;58(2):175-181.



8-year outcomes

Physician insights

Registry quick facts

 [Indications, Safety, and Warnings](#)

Endurant™ II/Endurant™ IIs Stent Graft System

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.

For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Important Reminder:

This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.